| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.15 | 0.02 |
| mRNA | manumycin A | CTRPv2 | pan-cancer | AAC | -0.074 | 0.02 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.08 | 0.02 |
| mRNA | SNS-032 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.02 |
| mRNA | temsirolimus | FIMM | pan-cancer | AAC | 0.35 | 0.02 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.097 | 0.02 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.03 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.12 | 0.03 |
| mRNA | BI-2536 | FIMM | pan-cancer | AAC | 0.27 | 0.03 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.03 |